DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trialECCO '18 Vienna
2018
DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trialsECCO '18 Vienna
2018
DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programmeECCO '18 Vienna
2018
DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-respondersECCO '18 Vienna
2018
DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitisECCO '18 Vienna
2018
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s diseaseECCO '18 Vienna
2018
DOP030: The efficacy of home telemonitoring vs. conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel diseaseECCO '18 Vienna
2018
DOP031: Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practiceECCO '18 Vienna
2018
DOP032: Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American surveyECCO '18 Vienna
2018
DOP033: Trends in epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based studyECCO '18 Vienna
2018
DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shiftECCO '18 Vienna
2018
DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)ECCO '18 Vienna
2018
DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)ECCO '18 Vienna
2018